Cell News and Research

RSS

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.

29 Sep 2010

Bayer Schering collaborates with Ligon to apply SMM technology for first-in-class drug discovery

Ligon Discovery, the innovator of Small Molecule Microarray technology, today announced that it has partnered with Bayer Schering Pharma AG, Germany, to apply its proprietary Small Molecule Microarray screening platform (SMM) to discover potential first-in-class drug candidates for new disease targets.

29 Sep 2010

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

YM BioSciences Inc., today reported that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

29 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

First Edition: September 29, 2010

In today's headlines, reports about the continuing politics surrounding the health overhaul, as both parties vie for the loyalty of older voters and First Lady Michelle Obama steps up efforts to promote the new law.

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Researchers primed to contribute next phase in search and discovery: Elsevier survey

Elsevier, a world-leading publisher of scientific, technical and medical information products and services, today released highlights from a new survey that reveals researchers around the globe are not only ready for the next phase in search and discovery, but also prepared to actively contribute to making it a reality.

29 Sep 2010

Cancer-causing mutations have minimum effect on tumor growth: Research

Individual cancer causing mutations have a minute effect on tumor growth, increasing the rate of cell division by just 0.4 percent on average, according to new mathematical modeling by scientists at Harvard University, Johns Hopkins University, and other institutions.

29 Sep 2010

Researchers identify gene activator that allows stem cells to transform any type of cell

Emerging Healthcare Solutions, Inc. was energized Monday by news that researchers in North Carolina may have identified the gene activator that allows stem cells to reproduce and become any type of cell in the body.

29 Sep 2010

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010

MRSA survivors to share experience at World MRSA Day kickoff event

No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.

29 Sep 2010

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

29 Sep 2010

Circulating tumor cells may be promising alternative for tumor biopsies

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

CAP cells produce high virus titers upon influenza strain infection

CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

29 Sep 2010

Scientists develop NIA assay to determine drug's differential effects in tumor cells

A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.We are making progress toward the goal of understanding how drugs work in different individuals, said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine.

29 Sep 2010

Morphotek announces first therapeutic monoclonal antibody for clinical development

Morphotek, Inc., a subsidiary of Eisai Inc., today announced that a monoclonal antibody has been selected for advancement to clinical development under the terms of its March 2009 collaboration agreement with Human Genome Sciences, Inc.

29 Sep 2010

Study finds naturally-derived trehalose inhibits fat cell hypertrophy

Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.

29 Sep 2010

New topical microbicide gel can prevent HIV transmission

Amyloid protein structures are best known for the troubles they pose in the brains of Alzheimer's patients. Now researchers are trying to exploit their presence in a very different place in semen to find a new way to stop HIV.

29 Sep 2010

Sanford-Burnham receives five-year core grant renewal from NCI

The Cancer Center at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has received a five-year core grant renewal from the National Cancer Institute (NCI).

29 Sep 2010

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Roche announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium throughput cell analyzer that utilizes impedance readings to monitor cardiac beating and cellular events in real time.

From Roche Sequencing and Life Science 29 Sep 2010

Cell News and Research

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

Bayer Schering collaborates with Ligon to apply SMM technology for first-in-class drug discovery

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

First Edition: September 29, 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Researchers primed to contribute next phase in search and discovery: Elsevier survey

Cancer-causing mutations have minimum effect on tumor growth: Research

Researchers identify gene activator that allows stem cells to transform any type of cell

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

MRSA survivors to share experience at World MRSA Day kickoff event

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

Circulating tumor cells may be promising alternative for tumor biopsies

CAP cells produce high virus titers upon influenza strain infection

Scientists develop NIA assay to determine drug's differential effects in tumor cells

Morphotek announces first therapeutic monoclonal antibody for clinical development

Study finds naturally-derived trehalose inhibits fat cell hypertrophy

New topical microbicide gel can prevent HIV transmission

Sanford-Burnham receives five-year core grant renewal from NCI

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics